Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomized, double blind, placebo-controlled, parallel group study to investigate efficacy and safety of ONO-2506PO compared to placebo, in the presence of riluzole, to patients diagnosed with amyotrophic lateral sclerosis (ALS), who have had onset of muscle weakness within 14 months of randomization.

Trial Profile

A multi-centre, randomized, double blind, placebo-controlled, parallel group study to investigate efficacy and safety of ONO-2506PO compared to placebo, in the presence of riluzole, to patients diagnosed with amyotrophic lateral sclerosis (ALS), who have had onset of muscle weakness within 14 months of randomization.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arundic acid (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
    • 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
    • 11 Dec 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top